Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
The aromatase inhibitors have been widely incorporated into the adjuvant breast cancer care of postmenopausal women with estrogen and/or progesterone receptor-positive breast cancer. Aromatase inhibitor use is associated with an increased risk of lowering bone mineral density and accelerating the risk of fragility fractures. Optimizing bone health includes appropriate nutrition and exercise, as well as screening for and treatment of low bone mass. Assessment of an individual's risk of fracture typically includes measuring the bone mineral density and other clinical risk factors, and there are evolving data as to the potential added information obtained by measuring biochemical markers of bone metabolism.
Barginear
Myra
M
Mount Sinai School of Medicine, Medical Oncology, One Gustave L. Levy Place, Box 1129, New York, NY 10029, USA. myra.barginear@mssm.edu
Clotfelter
Anne
A
Poznak
Catherine Van
CV
D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D001842:Bone and Bones / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced / Q000378:metabolism; D006801:Humans
D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor